Ozempic, the appetite-suppressing injection also known as semaglutide, currently costs $935.77 in the U.S. without insurance. But a new research report from Yale University, King’s College Hospital in London, and Doctors Without Borders published in JAMA Network Open Wednesday suggests that the price of the prescription drug could be lowered to a fraction of what it is right now, while still generating a profit.
The researchers calculated cost-based prices for one month of Ozempic, administered as an injectable of 0.77 mg weekly, by combining commercial trade shipment data from January 1, 2016 to March 31, 2023 with the cost of creating the drug, other operating expenses, a profit margin, and
→ Continue reading at Entrepreneur